Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

917 recalls, newest first

Class II · Moderate risk

Atorvastatin Calcium Tablets

Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.

Terminated Microbial contamination Mylan Institutional, Inc. (d.b.a. UDL Laboratories) NDC 51079-208-20 D-0622-2017
Class II · Moderate risk

Atorvastatin Calcium Tablets

Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.

Terminated Microbial contamination Mylan Pharmaceuticals Inc. NDC 0378-3953-09 D-0621-2017
Class II · Moderate risk

Atorvastatin Calcium Tablets

Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.

Terminated Microbial contamination Mylan Pharmaceuticals Inc. NDC 0378-3952-09 D-0620-2017
Class II · Moderate risk

Atorvastatin Calcium Tablets

Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.

Terminated Microbial contamination Mylan Pharmaceuticals Inc. NDC 0378-3951-09 D-0619-2017
Class II · Moderate risk

Atorvastatin Calcium Tablets

Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.

Terminated Microbial contamination Mylan Pharmaceuticals Inc. NDC 0378-3950-77 D-0618-2017
Class II · Moderate risk

Lactulose Solution

CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.

Terminated Microbial contamination VistaPharm, Inc. D-0463-2017
Class II · Moderate risk

Lactulose Solution

CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.

Terminated Microbial contamination VistaPharm, Inc. D-0462-2017
Class II · Moderate risk

Nystatin Oral Suspension

CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.

Terminated Microbial contamination VistaPharm, Inc. NDC 66689-037-99 D-0461-2017
Class II · Moderate risk

Phenytoin Oral Suspension

CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.

Terminated Microbial contamination VistaPharm, Inc. D-0460-2017
Class II · Moderate risk

Metoclopramide Oral Solution

CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.

Terminated Microbial contamination VistaPharm, Inc. D-0459-2017
Class II · Moderate risk

Nystatin Oral Suspension

CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.

Terminated Microbial contamination VistaPharm, Inc. NDC 66689-008-02 D-0457-2017
Class II · Moderate risk

Lactulose Solution

Microbial Contamination of Non-Sterile Products: bulk solution tested positive for the presence of the bacteria, Burkholderia cepacia.

Terminated Microbial contamination VistaPharm, Inc. NDC 66689-039-01 D-0146-2017
Class II · Moderate risk

Senna Syrup

CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.

Terminated Microbial contamination Pharmatech LLC NDC 0904-6289-09 D-1526-2016
Class II · Moderate risk

Senexon Liquid

CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.

Terminated Microbial contamination Pharmatech LLC NDC 0536-1000-59 D-1525-2016
Class II · Moderate risk

Diocto Syrup

CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.

Terminated Microbial contamination Pharmatech LLC NDC 0536-1001-85 D-1524-2016
Class II · Moderate risk

Aller-Chlor

CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.

Terminated Microbial contamination Pharmatech LLC NDC 0536-1025-47 D-1523-2016
Class II · Moderate risk

Ninjacof-A

CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.

Terminated Microbial contamination Pharmatech LLC NDC 23359-033-16 D-1522-2016

Recalls by year